Synthemax cuts hESC production cost say Geron and Corning

By Gareth Macdonald

- Last updated on GMT

Related tags: Stem cell

New Synthemax synthetic growth matrix promises improved scalability for large-scale hESC production which, say developers Geron and Corning, will cut cost of cell therapy manufacture.

Industrial production of human embryonic stem cells (hESCs) is problematic because the surface coating on which they are usually grown are expensive, subject to lot to lot variability and need to be tested to ensure they are pathogen-free.

Synthemax, in contrast, is designed to provide a synthetic contaminant growth matrix that supports the stable proliferation of undifferentiated hESCs in quantities suitable for cell therapy production.

The other advantage of the technology, according to Corning director of commercial technology Jeff Mooney, is that it can support cell differentiation after multiple passages.

Mooney cited data first presented at the World Stem Cell Summit in Baltimore last September showing that hESC grown on Synthemax were successfully differentiated into cardiomyocytes after as many as 20 growth cycles.

He added that in partnership with Geron Corning has developed “what we believe is the first and only synthetic surface in the world to enable this level of stem cell growth and differentiation​.”


Under the terms of the four year collaboration, Corning will be responsible for commercialising laboratory products that use the Synthemax matrix, the first of which, a 6-well culture plate, is already available to scientists in North America.

In return US cell therapy maker Geron, which retains rights to use the technology for the manufacture of certain undisclosed products, will receive royalty payments on all Synthemax sales.

Jane Lebkowski, Geron CSO, described the technology as “an enabling platform​” that will allow the development of new therapies, explaining that it “allows for more consistent, reliable and cost effective manufacturing​.”

Related news

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us